Dietary and lifestyle indices for hyperinsulinemia and odds of MAFLD in overweight and obese children and adolescents
Authors:
Open Access
- 6 February 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Abstract
Lifestyle and dietary intake play a pivotal role in development of metabolic dysfunction-associated fatty liver disease(MAFLD). We performed this cross-sectional study to evaluate the association between lifestyle and dietary insulinemic potential and odds of MAFLD in overweight and obese children and adolescents. The insulinemic potential of the diet and lifestyle was assessed by computing the scores of the empirical dietary index for hyperinsulinemia(EDIH), the empirical lifestyle index for hyperinsulinemia(ELIH), the empirical dietary index for insulin resistance(EDIR), and the empirical lifestyle index for insulin resistance(ELIR). MAFLD was diagnosed according to the consensus definitions. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression. A total of 334 (49.1% boys) with mean ± SD age and BMI-for-age-Z-score of 9.3 ± 1.8 and 2.55 ± 0.69, respectively, were enrolled. After adjusting for all potential confounders, participants in the highest quartile of ELIH score had greater odds of developing MAFLD (OR:3.50;95%CI:1.49–8.22) compared with those in the lowest quartile. This association remained significant among boys and pubertal ones. However, no significant association between EDIH, EDIR, or ELIR and odds of MAFLD was found. Our study suggests that the collective insulinemic potential of dietary intake, BMI, and physical activity is associated with increased odds of MAFLD.Keywords
This publication has 57 references indexed in Scilit:
- Global Prevalence of Overweight and Obesity in Children and AdolescentsJAMA Pediatrics, 2024
- Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver FibrosisDigestive Diseases and Sciences, 2024
- Metabolic-associated fatty liver disease and the risk of cardiovascular diseaseClinics and Research in Hepatology and Gastroenterology, 2022
- Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseasesThe Lancet Gastroenterology & Hepatology, 2021
- Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology, 2020
- Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic healthThe Lancet Gastroenterology & Hepatology, 2020
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJournal of Hepatology, 2020
- Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategiesThe Lancet Diabetes & Endocrinology, 2019
- Child and adolescent obesity: part of a bigger pictureThe Lancet, 2015
- Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adultsObesity, 2012